![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
AN Schoffelmeer, YH Yao, TL Gioannini, JM Hiller, D Ofri, BP Roques and EJ Simon
Department of Pharmacology, Free University, Medical Faculty, Amsterdam, The Netherlands.
In a modified Krebs buffer at 37 degrees C, the selective mu agonist [3H] D-Ala2,MePhe4,Gly-ol5]enkephalin [( 3H]DAMGO) and the nonselective mu/delta agonist human [125I]beta-endorphin [( 125I]beta-endH) bound to rat striatal membranes with a Kd of about 7 and 5 nM and a Bmax of about 95 and 260 fmol/mg of protein, respectively, consistent with labeling of mu receptors by the former ligand and labeling of both mu and delta receptors by the latter. The binding of 2 nM [125I]beta-endH was displaced by unlabeled DAMGO (IC50 30 nM), [D-Ala2-D- Leu5]enkephalin (IC50 60 nM) as well as by the selective delta agonists [D-Ser2(O-tert-butyl),Leu5]enkephalyl-Thr6 (DSTBULET, IC50 500 nM) and Tyr-Ala-Phe-Asp-Val-Val-Gly-NH2 (IC50 700 nM) in a monophasic manner within 2 to 3 log concentration units, suggesting an allosteric interaction between mu and delta sites labeled by [125I]beta-endH under these conditions. Accordingly, 500 nM DSTBULET caused almost 40% inhibition of the apparent Bmax without changing the apparent Kd of [3H] DAMGO. The kappa agonist U 50,488 was ineffective as competing ligand even at a concentration of 10 microM. Upon affinity cross- linking of [125I]beta-endH (2 nM) to rat striatal mu- and delta-opioid receptors, sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the solubilized tissue under reducing conditions followed by autoradiography of the dried gels revealed a major broad band of covalently labeled protein with an apparent molecular weight of 80 kDa.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
 |
|
  L. F. Agnati, S. Ferre, C. Lluis, R. Franco, and K. Fuxe Molecular Mechanisms and Therapeutical Implications of Intramembrane Receptor/Receptor Interactions among Heptahelical Receptors with Examples from the Striatopallidal GABA Neurons Pharmacol. Rev., September 1, 2003; 55(3): 509 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Wang and V. M. Pickel Preferential Cytoplasmic Localization of {delta}-Opioid Receptors in Rat Striatal Patches: Comparison with Plasmalemmal {micro}-Opioid Receptors J. Neurosci., May 1, 2001; 21(9): 3242 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. W. Hurley and D. L. Hammond Contribution of Endogenous Enkephalins to the Enhanced Analgesic Effects of Supraspinal {micro} Opioid Receptor Agonists after Inflammatory Injury J. Neurosci., April 1, 2001; 21(7): 2536 - 2545. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. W. D. Matthes, C. Smadja, O. Valverde, J.-L. Vonesch, A. S. Foutz, E. Boudinot, M. Denavit-Saubie, C. Severini, L. Negri, B. P. Roques, et al. Activity of the delta -Opioid Receptor Is Partially Reduced, Whereas Activity of the kappa -Receptor Is Maintained in Mice Lacking the µ-Receptor J. Neurosci., September 15, 1998; 18(18): 7285 - 7295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. J. Schultz, A. K. Hsu, and G. J. Gross Ischemic Preconditioning in the Intact Rat Heart Is Mediated by {delta}1- But Not µ- or {kappa}-Opioid Receptors Circulation, April 7, 1998; 97(13): 1282 - 1289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Hepburn, P. J. Little, J. Gingras, and C. M. Kuhn J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1350 - 1356. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
